Precision BioSciences Inc Announces In Vivo Gene Editing Collaboration with Novatris Transcript
Good day. And thank you for standing by. Welcome to the Precision Biosciences in vivo gene editing collaboration with Novartis. (Operator Instructions). Please be advised that today's conference may be recorded. I would now like to hand the conference over to your speaker today, Alex Kelly, Chief Financial Officer, please go ahead.
Thank you, [Catherine]. And good morning, everyone. And welcome to our webcast to discuss our recently announced in vivo gene editing collaboration with Novartis and the financing that we completed yesterday, which together extend our cash runway to the end of 2024.
Before we begin, I'd like to remind you that the statements we make today on this webcast that do not relate to material -- relate to matters of historical fact, our future expectations, and forward-looking statements.
Our forward looking statements are within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
